Idorsia touts new sleep drug data ahead of PhIII; Tetraphase out to raise $65M

Actelion spinout Idorsia says it scored positive data from two Phase II studies of a new sleep drug called ACT-541468. Investigators say that they designed this drug with two key features in mind: keep people asleep through the night with few lingering side effects after they wake up. They tested the drug in 418 patients, reporting on top-line results. And now the company plans to move into Phase III. “I am delighted to see that the positive readouts from this comprehensive Phase 2 program are consistent with our preclinical predictive models, for both adult and elderly patients with insomnia,” said CSO Martine Clozel.

Tetraphase $TTPH is the latest biotech to follow up on positive data with a stock offering. The company is looking to raise $65 million.

→ France’s Servier has taken an option on an osteoarthritis drug discovered at Galapagos. Servier gets global rights outside the US in the deal, paying a €6 million license fee and committing to €290 million in milestones. The mechanism of action of GLPG1972/S201086 targets a cartilage degrading enzyme called ADAMTS-5.

→ Prominent UK investor Neil Woodford took up the case in favor of AstraZeneca this week. After the MYSTIC fail damaged the pharma giant’s shares, Woodford — like CEO Pascal Soriot — insisted there are plenty of reasons to believe that AstraZeneca can succeed.

The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 21,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Bulletin Healthcare

Immuno Oncology 360